CLGN Stock Overview
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CollPlant Biotechnologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.85 |
| 52 Week High | US$8.90 |
| 52 Week Low | US$4.22 |
| Beta | 0.41 |
| 1 Month Change | 14.71% |
| 3 Month Change | 1.74% |
| 1 Year Change | -15.22% |
| 3 Year Change | -57.61% |
| 5 Year Change | 14.70% |
| Change since IPO | -68.32% |
Recent News & Updates
Recent updates
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow
Feb 03
Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?
Nov 02CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business
Sep 06Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation
Jul 14Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation
Mar 02Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth
Nov 10CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M
Aug 25We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth
Jul 22CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 22CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company
Aug 05Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation
Jul 29The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business
Jun 09Shareholder Returns
| CLGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.0% | 3.4% | 1.6% |
| 1Y | -15.2% | 3.8% | 25.1% |
Return vs Industry: CLGN underperformed the US Biotechs industry which returned 2.8% over the past year.
Return vs Market: CLGN underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| CLGN volatility | |
|---|---|
| CLGN Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CLGN has not had significant price volatility in the past 3 months.
Volatility Over Time: CLGN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 75 | Yehiel Tal | www.collplant.com |
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company’s products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds.
CollPlant Biotechnologies Ltd. Fundamentals Summary
| CLGN fundamental statistics | |
|---|---|
| Market cap | US$67.00m |
| Earnings (TTM) | -US$7.02m |
| Revenue (TTM) | US$10.96m |
6.1x
P/S Ratio-9.5x
P/E RatioIs CLGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLGN income statement (TTM) | |
|---|---|
| Revenue | US$10.96m |
| Cost of Revenue | US$1.99m |
| Gross Profit | US$8.97m |
| Other Expenses | US$15.99m |
| Earnings | -US$7.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | 81.83% |
| Net Profit Margin | -64.05% |
| Debt/Equity Ratio | 0% |
How did CLGN perform over the long term?
See historical performance and comparison